glp-1 news today pharma New Pill Foundayo (Orforglipron) Gets FDA Approval for Obesity Societies take stand against off-brand

Recently, the dual GIPR/GLP-1R co-agonist, tirzepatide, has demonstrated a marked effect on body weight in individuals with overweight and obesity, and Phase III trials of this drug are expected to be completed in 2023 [28]

As we age, growth hormone levels naturally decline slowing metabolism and reducing muscle mass

Top brand choice We guarantee the lowest price on all of our prescription products

Milder GI symptoms like nausea, constipation, or mild discomfort are common during GLP-1 initiation and usually resolve within weeks

Promote a Lean Physique: Regular use supports fat reduction while helping you achieve a toned and sculpted body

More deets on how peptides can help with testosterone are a click away in our testosterone support guide